Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ASL Napoli 2 Nord - Ospedale Santa Maria delle Grazie

Verified siteinfo

Italy Via domitiana, 80078 Pozzuoli, Italy

  • 7 trials recruiting
  • Colorectal cancer metastatic · Bladder cancer · Breast cancer metastatic
  • Adult patients

About Specializations

ASL Napoli 2 Nord - Ospedale Santa Maria delle Grazie in Pozzuoli, Italy specialises in clinical trials of conditions such as Colorectal cancer metastatic, Bladder cancer, Breast cancer metastatic, Hormone-refractory prostate cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on innovative treatment strategies for bladder cancer. The center is exploring the potential of combining immunotherapy agents such as durvalumab and tremelimumab with enfortumab vedotin to enhance therapeutic outcomes for patients who are ineligible for traditional treatments like cisplatin.

  • Immunotherapy Combinations
  • Advanced Bladder Cancer Treatments
  • Non-Cisplatin Therapies

Through rigorous clinical trials, the center aims to improve the safety and efficacy of these novel combinations, offering new hope to patients with limited treatment options.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via domitiana80078 PozzuoliItaly
Open in maps ↗
Recruiting now
7 trials
Conditions studied
8
Partner status
Verified site

More sites in PozzuoliItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Colorectal cancer metastatic

Recruiting

Study on Regorafenib for Patients with Advanced RAS-Mutant Colorectal Cancer Using Regorafenib and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Triple negative breast cancer

Recruiting

Study of Atezolizumab, Carboplatin, and Nab-Paclitaxel for Patients with Metastatic Triple-Negative PD-L1 Positive Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Consorzio Oncotech

Colorectal cancer metastatic

Recruiting

Study on Cetuximab, Irinotecan, and Fluorouracil for First-Line Treatment in Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Colorectal cancer metastatic

Recruiting

Study of Valproic Acid, Panitumumab, and Irinotecan for Patients with Metastatic Colorectal Cancer with RAS/BRAF Wild-Type

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Metastatic renal cell carcinoma

Recruiting

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Consorzio Oncotech

Colorectal cancer metastatic

Recruiting

Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Breast cancer metastatic

Recruiting

Study of Palbociclib and Fulvestrant for Women with Advanced Breast Cancer After Previous CDK4/6 Inhibitor and Hormonal Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Consorzio Oncotech

Rectal cancer

Not recruiting

Study on Valproic Acid with Bevacizumab and Oxaliplatin/Fluoropyrimidine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.